BSE See NSE See 38,182.08
141.51 (0.37%)

DSIJ Mindshare

Glenmark to launch higher strength version of oral antiviral FabiFlu

Anthony Fernandes / Article rating: 4.7

Global pharma major, Glenmark Pharmaceuticals announced on Thursday that it is launching a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. Glenmark Pharmaceuticals was the first company in the country to have received the regulator’s approval for 400 mg dosage form.

Indian Oil Board gives go-ahead for company’s Rs 13,805 crore PX-PTA complex

Anthony Fernandes / Article rating: 4.2

Indian Oil Corporation announced today that the company’s board had approved the implementation of an Integrated Para-Xylene (PX) and Purified Terephthalic Acid (PTA) complex project at Paradip, Odisha, at an estimated investment of Rs 13,805 crore. The PX-PTA complex is estimated to be completed by 2024 and will be integrated with the company’s Paradip Refinery which is operational since 2015.

Lupin gets USFDA tentative approval for type 2 diabetes tablets

Anthony Fernandes / Article rating: 5.0

Pharma-major, Lupin Limited, announced that it has received tentative approval for its Empagliflozin and Linagliptin tablet in the strengths of 10 mg/5 mg and 25 mg/5 mg from United States Food and Drug Administration (USFDA), to commercialise a generic version of Glyxambi tablets, of Boehringer Ingelheim Pharmaceuticals, Inc.